Genetic testing can improve selection of women with ER positive breast cancer for ten rather than five years of hormonal therapy

Bookmark and Share
Published: 1 Apr 2014
Views: 2361
Prof Mitch Dowsett - The Institute of Cancer Research, London, UK

Prof Mitch Dowsett talks to ecancertv at EBCC 9 about the research he presented on long term hormonal therapy for ER positive breast cancer.

Genetic analyses of results from 1125 postmenopausal women being treated for oestrogen responsive breast cancer have shown that some of them are more likely than others to have a late recurrence of their cancer and might benefit from ten years of hormone therapy rather than five.